Work

Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors

Year: 2025

Type: article

Abstract: Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod primes plasmacytoid dendritic cells (DCs) to produce type I interferon, thereby sensitizing conventional DCs in tumors to local Toll-like receptor 7 activation. This approach triggers c-Jun-dependent IL-12 production and CCL2-mediated plasmacytoid DC recruitment, enabling localized and systemic tumor suppression. Importantly, the therapy synergizes with PD-1 blockade to prevent recurrence, representing a significant advance in DC-targeted cancer immunotherapy.

Source: Research

DOI: 10.34133/research.0739

Authors: Haiting Xu, Chenghui Wang, Bo Xiao

Institutions: Southwest University, University of Electronic Science and Technology of China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,500